Amarin
Open
$14.00
Prev. Close
$14.04
High
$14.00
Low
$13.94
Market Snapshot
-13.00
$1.15B
80
Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
emptyResult
Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Recently from Cashu
Amarin's Q4 Earnings: Strong Performance and Strategic Vision for Cardiovascular Therapy Growth
Amarin Corp: Poised for Growth Through Innovation and Strategic Expansion In its recent Q4 earnings report, Amarin Corp showcases a robust financial performance and strategic developments pivotal to i…
Amarin Reports Strong Q4 Performance and Strategic Developments in Cardiovascular Market
Amarin Corp. Solidifies Market Position with Strategic Developments and Strong Q4 Performance Amarin Corp., a key player in the cardiovascular therapy market, reports a strong financial performance fo…
Amarin Corp's Strong Revenue Growth and Strategic Expansion in Cardiovascular Therapies
Amarin Corp's Promising Growth in Cardiovascular Therapies Amarin Corp is currently experiencing significant growth within the cardiovascular therapeutic market, primarily driven by the increasing sal…
Amarin Reports Strong Financials, Exceeding Expectations and Signaling Market Resilience
Amarin Reports Strong Financial Results, Underlining Market Resilience Amarin, a prominent player in the biopharmaceutical industry, announces its latest financial results, showcasing a significant up…